$695 | Single User
$2850 | Site License
$5650 | Global License

Physician Views: Repatha recommended for European approval – how will EU5 cardiologists utilise the PCSK9 inhibitor class?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 May 2015 | 229 | In Stock

Introduction

Scope


Amgen and Sanofi/Regeneron Pharmaceuticals may be locked in one of the most intriguing US drug regulatory races of recent memory, but it is the European Medicines Agency that has provided a first definitive regulatory action for the PCSK9 inhibitor class by recommending approval of Amgen's Repatha.


The EMA has recommended approval of a broad label for Repatha in Europe, which includes those patients with mixed dyslipidaemia who are unable to reach LDL-cholesterol reduction goals with statin therapy or whom are intolerant to statins. Furthermore, Phase III data for Repatha has demonstrated LDL-C reductions of 46 percent to 64 percent from baseline at week 12 in various patient populations with hyperlipidaemia.


How cardiologists utilise this drug class is, however, a very different matter. Data from ongoing outcomes studies – due to be published in 2017/18 – are expected to shape the longer-term uptake of the PCSK9 inhibitors, while other factors – such as pricing and access – will also play a prominent role on the European landscape (ViewPoints: Europe provides positive regulatory momentum for PCSK9 inhibitor class, but regional cardiologists likely to prescribe less than US counterparts).


Puchase Reasons


To better ascertain sentiment towards the PCSK9 inhibitor class, FirstWord Pharma is asking cardiologists based in France, Germany, Italy, Spain and the UK the following questions...


  • It has been estimated that the PCSK9 inhibitors will cost between 00 and 000 per patient per year in the US market; even factoring a likely price discount in Europe, how significant a role do you expect price to play in limiting the use of these drugs?

  • Prior to the availability of cardiovascular outcomes data for the PCSK9 inhibitor class (expected in 2017/18), what level of usage do you anticipate for the treatment of patients with HeFH or HoFH?

  • Prior to the availability of cardiovascular outcomes data for the PCSK9 inhibitor class, what level of usage do you anticipate for the treatment of patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or patients who are statin intolerant?

  • How significant a role do you expect an initial lack of cardiovascular outcomes data for this drug class to limit usage in statin-intolerant/LDL-C target non-achiever patients?

  • How much increased pressure do you expect to be under to ensure that patients have received the correct dosing/treatment with statins and/or other available therapies once the PCSK9 inhibitor class becomes available?
  • Table of Contents
    for Physician Views: Repatha recommended for European approval – how will EU5 cardiologists utilise the PCSK9 inhibitor class? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    229 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info
    Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Repatha recommended for European approval – how will EU5 cardiologists utilise the PCSK9 inhibitor class? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...